ARHGEF10L

Across TCGA pan-cancer cohorts, ARHGEF10L Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ARHGEF10L data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ARHGEF10L Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ARHGEF10L expression acts as an unfavorable survival marker.

HNSC, LIHC, and UCEC are the cancer types where ARHGEF10L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	II,III,IV	0.219	0.715	.001	18	view →
LIHC	DFS	Median	II,III,IV	0.067	0.431	<.001	18	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
GBM	OS	Median	All	0.075	0.416	.011	3	view →
SKCM	OS	Median	II,III,IV	0.453	0.744	.007	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ARHGEF10L–HNSC (OS)

Open the HNSC breakdown →